Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. [electronic resource]
Producer: 20060717Description: 946-8 p. digitalISSN:- 0003-4967
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Antirheumatic Agents -- therapeutic use
- Arteritis -- drug therapy
- Cyclophosphamide -- therapeutic use
- Endothelium, Vascular -- drug effects
- Female
- Humans
- Immunosuppressive Agents -- therapeutic use
- Infliximab
- Laser-Doppler Flowmetry
- Male
- Methylprednisolone -- therapeutic use
- Middle Aged
- Pilot Projects
- Statistics, Nonparametric
- Time Factors
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.